Table 1 Demographic and clinical characteristics of the pediatric discovery inception cohort and pediatric validation cohort
DISCOVERY | VALIDATION | ||||||
|---|---|---|---|---|---|---|---|
Uppsala pediatric IBD inception cohort (n = 94) | IBSEN III pediatric cohort (n = 117) | ||||||
IBD (n = 58) | Symptomatic controls (n = 36) | P-value | IBD (n = 80) | Symptomatic controls (n = 37) | P-value | ||
Age, median (IQR 1–3) | 15 (12-16) | 12 (9-16) | 0.02 | 14 (10-16) | 12 (7-14) | 0.003 | |
Males, n (%) | 35 (60) | 16 (44) | 0.13 | 45(57) | 23 (62) | 0.63 | |
BMI, median kg/m2 (IQR 1–3) | 19 (18-21) | 17 (16-19) | 0.01 | 18 (16-21) | 17 (16-20) | 0.14 | |
Blood samples, n (%) | 58 (100) | 36 (100) | 80 (100) | 37 (100) | |||
hsCRP, median (IQR 1–3) | 5 (0.8-12) | 0.5 (0.2–2) | <0.001 | 2.9 (0.6-8.6) | 0.5 (0.3–1.8) | <0.001 | |
Albumin, median (IQR 1–3) | 38 (34-40) | 39 (37-41) | 0.03 | 37 (35-41) | 41 (39-44) | <0.001 | |
Fecal samples, n (%) | 53 (91) | 28 (78) | 57 (72) | 20 (54) | |||
Fecal Calprotectin, median (IQR 1–3) | 1334 (739-2112) | 69 (40-448) | <0.001 | 861 (260-1801) | 87 (53-124) | <0.001 | |
Subtype IBD (%) | |||||||
Crohn’s disease | 44 (76) | NA | 53 (67) | NA | |||
Ulcerative colitis | 12 (20) | NA | 21 (25) | NA | |||
IBD-Unclassified | 2 (3) | NA | 6 (8) | NA | |||
Age at CD diagnosis, n (%) | |||||||
A1a (<10 years) | 6 (13) | NA | 7 (13) | NA | |||
A1b (10-16 years) | 32 (73) | NA | 39 (74) | NA | |||
A2 ( ≥ 17 years) | 6 (13) | NA | 7 (13) | NA | |||
Location of CD, n (%) | |||||||
L1 (terminal ileum) | 12 (27) | NA | 8 (15) | NA | |||
L2 (colon) | 17 (39) | NA | 12 (23) | NA | |||
L3 (ileocolon) | 15 (34) | NA | 27 (51) | NA | |||
L4 A* (upper GI) | 10 (22) | NA | 5 (9) | NA | |||
L4 B** (upper GI) | 0 (0) | NA | 1 (2) | NA | |||
Behavior of CD, n (%) | |||||||
B1 (non-stricturing, non-penetrating) | 41 (93) | NA | 44 (83) | NA | |||
B2 (stricturing) | 3 (7) | NA | 8 (15) | NA | |||
B3 (penetrating) | 0 (0) | NA | 1 (2) | NA | |||
p (perianal disease) | 9 (20) | NA | 8 (15) | NA | |||
NA | |||||||
PCDAI, median (IQR1-3) | 40 (29-56) | NA | 15 (10-25) | NA | |||
Age at UC diagnosis, n (%) | |||||||
A1a (<10 years) | 0 (0) | NA | 5 (25) | NA | |||
A1b (10–16 years) | 12 (86) | NA | 10 (50) | NA | |||
A2 (≥17 years) | 2 (14) | NA | 5 (25) | NA | |||
Extent of UC, n (%) | |||||||
E1 (proctitis) | 2 (17) | NA | 6 (30) | NA | |||
E2 (left sided) | 2 (17) | NA | 3 (15) | NA | |||
E3 (extensive) | 7 (58) | NA | 3 (15) | NA | |||
E4 (pancolitis) | 1 (8) | NA | 8 (40) | NA | |||
PUCAI, median (IQR 1–3) | 43 (30-49) | NA | 25 (15-40) | NA | |||
